Streetbeat News

AGIO

Agios Pharmaceuticals, Inc.

https://www.agios.com

Industry

Biotechnology

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Open

34.32

Mkt cap

Volume

High

35.30

P/E Ratio

3.03

52-wk high

62.58

Low

33.75

Div yield

N/A

52-wk low

27.14

Agios Pharmaceuticals (AGIO) reported mixed Q4 2024 results with a wider-than-expected loss. However, its sole marketed drug, Pyrukynd, contributed to year-over-year revenue growth.

Portfolio Pulse from

February 14, 2025 | 2:45 pm

Agios Pharmaceuticals, Inc. (AGIO) held its Q4 2024 earnings conference call on February 13, 2025. Key company participants included CEO Brian Goff, CMO Sarah Gheuens, CCO Tsveta Milanova, CFO Cecilia Jones, and VP Chris Taylor. The call was attended by analysts from major financial institutions.

Portfolio Pulse from

February 13, 2025 | 6:45 pm

Agios Pharmaceuticals (AGIO) reported a Q4 loss of $1.74 per share, slightly wider than the Zacks Consensus Estimate of $1.73. However, the company exceeded revenue expectations.

Portfolio Pulse from

February 13, 2025 | 2:00 pm

Agios Pharmaceuticals has reported its Q4 and full-year 2024 financial results, highlighting the regulatory filing for Mitapivat (PYRUKYND®) for treating thalassemia in multiple regions, with a PDUFA goal date set for September 7, 2025.

Portfolio Pulse from

February 13, 2025 | 11:45 am

Agios Pharmaceuticals, Inc. will host a conference call and webcast on February 13, 2025, to discuss their fourth quarter and full year 2024 financial results.

Portfolio Pulse from

February 06, 2025 | 12:15 pm

The FDA has accepted Agios Pharmaceuticals' supplemental New Drug Application (sNDA) for Pyrukynd, which could become the first oral therapy for all thalassemia subtypes. A decision is expected by September 7.

Portfolio Pulse from

January 09, 2025 | 2:30 pm

Agios Pharmaceuticals' mitapivat receives orphan medicinal product designation from the European Commission for sickle cell disease, following a similar designation by the FDA in 2020.

Portfolio Pulse from

December 18, 2024 | 12:15 pm

Agios Pharmaceuticals' stock (AGIO) dropped over 20% due to reports of an unexpected side effect associated with its drug Pyrukynd in thalassemia patients.

Portfolio Pulse from

December 10, 2024 | 5:00 pm

The Zacks Medical-Products industry is expected to benefit from rising demand for medical procedures and cost-cutting initiatives. Stocks like RMD, HAE, PAHC, and AGIO are well-positioned to capitalize on these favorable conditions.

Portfolio Pulse from

December 04, 2024 | 4:00 pm

The article discusses the performance of Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) compared to their sector this year.

Portfolio Pulse from

November 26, 2024 | 4:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.